Core Viewpoint - The company, 拨康视云-B, has seen a significant increase in its stock price, with a rise of over 80% in the past week, following the successful patent applications for its core product CBT-009 in Japan and Europe [1] Group 1: Stock Performance - The stock price of 拨康视云-B increased by over 4% during intraday trading and is currently up by 2.71%, priced at 8.72 HKD, with a trading volume of 6.75 million HKD [1] Group 2: Patent and Product Development - The company announced that its wholly-owned subsidiary, ADS Therapeutics LLC, has successfully applied for patents in Japan and Europe for CBT-009, which is one of its core products [1] - The successful patent application is considered a significant milestone in the development process of CBT-009, enhancing its global coverage and facilitating commercialization [1] Group 3: Future Collaborations - The company anticipates that the patent success will enable collaborations with major pharmaceutical companies for the production, development, and distribution of CBT-009 in key high-end markets like Japan and Europe [1] - These collaborations and licensing arrangements are expected to enhance and accelerate the global commercialization potential of CBT-009 [1]

Group 1 - The core viewpoint of the article highlights the significant stock price increase of Bolekang Shiyun-B (02592), which rose over 4% during trading and has accumulated a gain of over 80% in the past week [1] - As of the report, the stock price is at 8.72 HKD with a trading volume of 6.7514 million HKD [1] - The company announced that its wholly-owned subsidiary, ADS Therapeutics LLC, has successfully applied for patents in Japan and Europe for its core product CBT-009, marking an important milestone in its development process [1] Group 2 - The successful patent applications are expected to enhance the global coverage of CBT-009 and facilitate its commercialization [1] - The company anticipates establishing licensing arrangements with major pharmaceutical companies for the production, development, and distribution of CBT-009 in Japan and Europe, which are key high-end markets [1] - These collaborations and licensing agreements are expected to boost and accelerate the global commercialization potential of CBT-009 [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | | | I. 法定/註冊股本變動 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02592 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.0001 | USD | | 200,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.0001 | USD | | 200,000 | 公司名稱: Cloudbreak Pharma Inc. 呈交日期: 2025年12月1日 本月底法定/註冊股本總額： USD ...

Core Viewpoint - The stock of Bolekang Vision Cloud-B (02592) has surged over 10% today, with a cumulative increase of nearly 70% this week, driven by positive news regarding patent approvals for its core product CBT-009 [1] Group 1: Stock Performance - As of the latest update, the stock price is at 7.9 HKD, with a trading volume of 6.2189 million HKD [1] - The stock has shown significant growth, with a weekly increase close to 70% [1] Group 2: Patent Approval and Product Development - Bolekang Vision Cloud announced that its wholly-owned subsidiary, ADS USA, has successfully obtained patents from both the Japan Patent Office and the European Patent Office for CBT-009 [1] - CBT-009 is a new atropine eye formulation aimed at treating myopia in children and adolescents aged 5 to 19 [1] - The company anticipates establishing licensing arrangements with major pharmaceutical companies for the production, development, and distribution of CBT-009 in Japan and Europe [1] Group 3: Market Dynamics and Investor Sentiment - The upcoming expiration of lock-up shares for two cornerstone investors on January 3, 2026, is noted, which may impact stock performance [1] - The stock's recent performance suggests a lack of institutional funding, leading to insufficient domestic allocation [1] - Initial trading and dark pool performance were below expectations, potentially due to over-commitment by anchor participants, resulting in a sell-off [1]

（来源：四大新鲜事儿） 来源：四大新鲜事儿 港股上市公司拨康视云-B（02592.HK）于2025年11月27日发布了《更换核数师》。公告显示，董事会 宣布，罗兵咸永道会计师事务所已辞任该公司核数师，自2025年11月27日起生效。由于该公司与罗兵咸 永道未能就审核该集团截至2025年12月31日止财政年度（「2025财年」）的综合财务报表的审核费用达 成共识，应该公司要求，罗兵咸永道已同意辞任该公司核数师。 董事会进一步宣布，根据审核委员会的推荐，国卫会计师事务所有限公司已获委任为该公司核数师，自 2025年11月27日起生效，以填补罗兵咸永道辞任后的临时空缺。国卫的任期直至该公司下届股东周年大 会结束为止。 (股份代號：2592) 更換核數師 本公告乃由撥康視雲製藥有限公司(「本公司」,連同其附屬公司统稱「本集團」根據聯交所證券上市 規則([上市規則)第13.51(4)條作出。 核數師辭任 本公司董事會(「董事會」宣佈,羅兵威永道會計師事務所(羅兵咸永適)已辭任本公司核數師,自 2025年11月27日起生效。 详细如下： 香港交易及結算所有限公司及香港聯合交易所有限公司([聯交所])對本公告的内容概不負責 ...

Group 1 - Hong Kong's Hang Seng Index fell by 0.24%, down 61 points, closing at 25,884 points, while the Hang Seng Tech Index rose by 0.11% [1] - Pop Mart (09992) surged over 4%, leading the blue-chip stocks in the Hang Seng Index, supported by government encouragement for trendy toy consumption as the traditional sales season approaches [2] - GAC Group (02238) increased by over 12% following the full delivery of its Aion UT super model and the establishment of a solid-state battery production line [3] Group 2 - Zijin Mining International (02259) rose over 2% as its mining output increased, entering a growth phase in the coming years [4] - Dongyue Group (00189) saw a 4.62% increase, with institutions indicating strong demand for lithium batteries and potential price hikes for PVDF [5] - MicroPort Medical (00853) gained 5% as JPMorgan increased its stake by over HKD 900 million, with Bank of America expressing optimism about its surgical robot business [6] Group 3 - Bole Technology (02592) surged by 12.8% after its core product CBT-009 received patents in Japan and Europe [7] - Cambridge Technology (06166) rose over 4%, with expectations of significant shipments of its 1.6T optical modules in Q1 2026 [8] - Hezhima Intelligent (02533) and Joyson Electronics (00699) both increased by over 4% as they collaborate on a multi-chip platform for robotic domain control products [9] Group 4 - New stock Haiwei Co., Ltd. (09609) debuted with a 15% drop, being the second-largest capacitor film manufacturer in China [10] Group 5 - Food and Beverage ETF (Product Code: 515170) experienced a decline of 1.37% over the past five days, with a PE ratio of 20.73 times and a net redemption of HKD 1.719 million [12] - Gaming ETF (Product Code: 159869) rose by 4.31% over the past five days, with a PE ratio of 36.47 times and a net redemption of HKD 74.789 million [12] - Sci-Tech 50 ETF (Product Code: 588000) fell by 1.21% over the past five days, with a high PE ratio of 147.81 times and a net redemption of HKD 1.54 billion [12]

Group 1 - The stock of Boke Vision Cloud-B (02592.HK) has increased by over 10% and has accumulated a rise of nearly 70% this week [2] - As of the time of reporting, the stock is up 8.82%, trading at 7.9 HKD, with a transaction volume of 6.2189 million HKD [2]

Core Viewpoint - The stock of Bolekang Vision Cloud-B (2592.HK) has surged over 11%, marking a total increase of over 70% in the past six days, with the share price surpassing 8 HKD and a market capitalization of 6.824 billion HKD [1] Group 1 - Bolekang Vision Cloud-B announced the acquisition of two patents in Japan and Europe for its core product CBT-009, which is aimed at delaying myopia and treating eye diseases [1] - The company is expected to collaborate with major pharmaceutical firms to establish licensing arrangements for the production, development, and distribution of CBT-009 in Japan and Europe, which are key high-end markets for the product [1] - These collaborations and licensing arrangements are anticipated to enhance and accelerate the global commercialization potential of CBT-009 [1]

Core Viewpoint - The stock of Bolekang Vision Cloud-B (02592) has surged over 10% today, with a cumulative increase of nearly 70% this week, driven by positive news regarding patent approvals for its core product CBT-009 [1] Group 1: Stock Performance - As of the latest update, the stock is up 8.82%, trading at 7.9 HKD, with a transaction volume of 6.2189 million HKD [1] - The significant rise in stock price indicates strong market interest and potential investor confidence in the company's future prospects [1] Group 2: Product Development - Bolekang Vision Cloud announced that its wholly-owned subsidiary, ADS USA, has successfully obtained patents from the Japan Patent Office and the European Patent Office for CBT-009 [1] - CBT-009 is a novel atropine eye preparation aimed at treating myopia in children and adolescents aged 5 to 19 [1] - The company anticipates establishing licensing arrangements with major pharmaceutical companies for the production, development, and distribution of CBT-009 in Japan and Europe [1] Group 3: Market Context - A report highlighted that on January 3, 2026, two cornerstone investors of Bolekang Vision Cloud will face a lock-up expiration, which could impact stock liquidity [1] - The stock's performance has been characterized by a lack of institutional funding, leading to insufficient national placement, which may have contributed to initial underperformance in the dark market and on the listing day [1]

Core Viewpoint - The stock price of Bolekang Shiyun-B (02592) has experienced a significant increase of over 50% during a recent five-day rally, drawing attention back to the company after a period of decline since its IPO [1][3]. Group 1: Stock Performance - Since its IPO on July 3, the stock price of Bolekang Shiyun has been in a downward trend, dropping 38% on its first day and remaining volatile with low trading volumes [2][5]. - The stock has seen less than 30 days of trading with a volume exceeding 1 million shares, indicating low investor interest [1][2]. - The recent surge in stock price coincides with the one-month countdown to the unlocking of cornerstone investor shares, raising concerns among investors about potential price corrections [1][5]. Group 2: Technical Analysis - The stock has been fluctuating within the Bollinger Bands since August, with no significant volume increase to support the price movements, indicating a lack of strong market interest [2][5]. - Despite touching the upper Bollinger Band on November 19, the stock experienced a 4.08% decline the following day, suggesting that the recent price increase may not be sustainable [2][5]. Group 3: Cornerstone Investors and Unlocking - Bolekang Shiyun's IPO involved the issuance of 60.582 million shares at an issue price of HKD 10.10, raising a total of HKD 612 million [5][6]. - Two cornerstone investors, Fucai Holdings and Reynold Lemkins, subscribed to a total of 17.72 million shares, representing approximately 2.11% of the total share capital, with a combined investment of USD 22.8 million [5][6]. - As of November 17, the stock price had fallen to HKD 4.33, resulting in a loss of approximately USD 13.03 million for the cornerstone investors, which narrowed to USD 6.41 million after the recent price increase [5][6]. Group 4: Company Fundamentals - Bolekang Shiyun is a clinical-stage ophthalmic biotechnology company focused on developing various therapies, with all its candidate drugs being self-developed [8][9]. - The company has reported net losses of approximately USD 67 million, USD 129 million, and USD 99 million for the years 2022 to 2024, totaling USD 295 million (approximately RMB 2.12 billion) [9][10]. - The lack of commercialized products and ongoing clinical trials contribute to the company's challenges in attracting investor interest [8][9].